2-(methylamino)-2-(naphthalen-1-yl)acetonitrile | 69243-82-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(methylamino)-2-(naphthalen-1-yl)acetonitrile
• 英文别名: 2-(methylamino)-2-naphthalen-1-ylacetonitrile
• CAS: 69243-82-9
• 化学式: C₁₃H₁₂N₂
• mdl: MFCD11186504
• 分子量: 196.252
• InChiKey: BRNHFUNFIKDOHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(methylamino)-2-(naphthalen-1-yl)acetonitrile 、 4-叔丁基苄溴 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以75%的产率得到(α-<4-(1,1-Dimethylethyl)phenylmethyl>-N-methyl>-amino)-1-naphthalinacetonitril
  参考文献：
  名称：

  Chiral derivatives of Butenafine and Terbinafine: synthesis and antifungal activity

  摘要：

  Two series of allylamines/benzylamines have been synthesised and evaluated for their antifungal activity towards Cryptococcus neoformans. All compounds are chiral derivatives of Butenafine and Terbinafine, having additional substituents at the carbon connected to the central nitrogen atom. In both series. the antifungal activity was strongly dependent on both the steric bulk and the electronic nature of the substituents. Compared to the parent compounds (Butenafine and Terbinafine), the activity was maintained when the hydrogen was replaced with a methyl group. Lower activity was observed for ethyl, whereas introduction of -CH2F, -CHF2, -CF3 or -CN substituents removed all antifungal activity. Testing of (R)- and (S)-N-(4-tert-butylbenzyl)-N-methyl-1-(naphthalen-1-yl)ethanamine against C. neoformans. Cryptococcus diffluens and Trichosporon cutaneum revealed that most of the activity resides in the (R)-enantiomer. The (R)-enantiomer performed as well as, or better (lower MIC values) than Butenafine against each test strain, suggesting that antimycotics based on this compound might be an improvement of existing Butenafine-based formulations. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.09.067

文献信息

• Imidazole-2-carbamates and process for their production and pharmaceutical compositions containing them.
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0000089A1

  公开（公告）日：1978-12-20

  Imidazole-2-carbamates represented by the formula wherein R is hydrogen or alkyl of 1-4 carbons, R1 is alkyl of 1-6 carbons and the naphthyl group is attached to the imidazole ring at the 1 or2 positions ofthe naphthyl ring, and the pharmaceutically acceptable salts thereof. These compounds are useful as centrally acting skeletal muscle relaxants. The compounds are prepared by ring closure of a compound of the formula

  由以下式子表示的咪唑-2-氨基甲酸酯 其中 R 是氢或 1-4 个碳原子的烷基，R1 是 1-6 个碳原子的烷基，萘基连接到咪唑环的 1 或 2 位，以及它们的药学上可接受的盐类。 这些化合物可用作中枢作用的骨骼肌松弛剂。 这些化合物的制备方法是将式
• US4110463A
  申请人：——

  公开号：US4110463A

  公开（公告）日：1978-08-29
• Chiral derivatives of Butenafine and Terbinafine: synthesis and antifungal activity
  作者：Erik Fuglseth、Eli Otterholt、Hanne Høgmoen、Eirik Sundby、Colin Charnock、Bård Helge Hoff

  DOI：10.1016/j.tet.2009.09.067

  日期：2009.11

  Two series of allylamines/benzylamines have been synthesised and evaluated for their antifungal activity towards Cryptococcus neoformans. All compounds are chiral derivatives of Butenafine and Terbinafine, having additional substituents at the carbon connected to the central nitrogen atom. In both series. the antifungal activity was strongly dependent on both the steric bulk and the electronic nature of the substituents. Compared to the parent compounds (Butenafine and Terbinafine), the activity was maintained when the hydrogen was replaced with a methyl group. Lower activity was observed for ethyl, whereas introduction of -CH2F, -CHF2, -CF3 or -CN substituents removed all antifungal activity. Testing of (R)- and (S)-N-(4-tert-butylbenzyl)-N-methyl-1-(naphthalen-1-yl)ethanamine against C. neoformans. Cryptococcus diffluens and Trichosporon cutaneum revealed that most of the activity resides in the (R)-enantiomer. The (R)-enantiomer performed as well as, or better (lower MIC values) than Butenafine against each test strain, suggesting that antimycotics based on this compound might be an improvement of existing Butenafine-based formulations. (C) 2009 Elsevier Ltd. All rights reserved.